Drilling Down on Interleukin-33

Program Description

Join us for this on demand activity that brings interleukin (IL)-33, an emerging therapeutic target in respiratory medicine, to center stage. This program will examine the evolving role of IL-33 as both a driver of inflammation and a regulator of gene expression, highlighting its signaling pathways and contribution to the pathophysiology of chronic respiratory disease and acute infection. Attendees will gain insight into the scientific rationale for targeting IL-33 in therapeutic development, along with the latest updates from ongoing clinical investigations of biologic agents designed to modulate its activity. Our faculty experts will share their perspectives through dynamic discussion and real-time engagement with participants.

Target Audience

This educational activity has been designed to educate pulmonologists, as well as critical care, infectious disease, and emergency medicine clinicians who manage patients with chronic obstructive pulmonary disease (COPD) or acute respiratory infections.

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

• Explain the pathophysiologic roles of IL-33 signaling in chronic obstructive pulmonary disease (COPD) and acute respiratory infections
• Compare the pharmacologic profiles of and published evidence for emerging biologic therapies targeting IL-33 for COPD and acute respiratory infections
• Integrate emerging biologic therapies into treatment algorithms for COPD or acute respiratory infections as they become available

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 70% or better on the posttest and complete the program evaluation.

Disclosures of Conflicts of Interest

Integritas Communications adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Professor James Dodd, MBChB, MRCP, PhD: Consulting Fees: AstraZeneca, Chiesi Farmaceutici S.p.A., GSK, Sanofi; Fees for non-CE services received directly from an ineligible company: AstraZeneca, GSK, Sanofi; Contracted Research (externally sponsored research funding to host institution): GSK; Other (support to attend conferences): AstraZeneca, GSK, F. Hoffmann-La Roche Ltd, Sanofi

Professor Tom Wilkinson, MA Cantab, MBBS, PhD, FRCP, FERS: Consulting Fees (e.g., advisory boards): AstraZeneca, bioMérieux, Enanta, GSK, Janssen, Sanofi, Synairgen, TidalSense; Contracted Research: AstraZeneca, bioMérieux, GSK, Janssen, Sanofi, Synairgen; Ownership Interest: Stock Options (or other ownership interest excluding diversified mutual funds): TidalSense

The Integritas planners and managers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this activity.

Contact Information

For information about this program, please contact us at info@exchangecme.com.